GlassScriptPhysician profile
Emily Prahl
NPI 1164070413
$2,139.47
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $777 · 2022: $969 · 2023: $52.39 · 2024: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $393.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $697.68 | 2021-2024 | Qelbree |
| Abbvie INC. | $460.73 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $261.94 | 2021-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.14 | 2022-2024 | Caplyta |
| Lundbeck LLC | $109.56 | 2021-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $103.06 | 2021-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $51.55 | 2021-2024 | Ingrezza |
| Neos Therapeutics, LP | $49.42 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $33.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.98 | 2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $30.94 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $24.49 | 2024 | Fanapt, Hetlioz |
| Adlon Therapeutics L.P. | $24.26 | 2021 | |
| Brainsway USA INC | $19.00 | 2022 | |
| Alkermes, INC. | $18.61 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $17.96 | 2023 | Xelstrym |
| Corium, LLC | $17.45 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $17.25 | 2024 | Auvelity |
| Ironshore Pharmaceuticals INC. | $16.98 | 2023 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $13.76 | 2024 | |
| Almatica Pharma LLC | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Prahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.